The Hybrid Closed-Loop System Tandem t:slim X2™ with Control-IQ Technology: Expert Recommendations for Better Management and Optimization
Open Access
- 20 October 2023
- journal article
- research article
- Published by Springer Nature in Diabetes Therapy
- Vol. 15 (1) , 281-295
Abstract
Technological advances in the management of diabetes, especially type 1 diabetes (T1D), have played a main role in significantly improving glycemic control of these patients in recent years. Undoubtedly, the most important advance has been the commercialization of hybrid closed-loop systems (HCL). Their effectiveness places them in the different guidelines from scientific societies as the gold standard for the treatment of people with T1D. However, obtaining the maximum performance from these systems requires a degree of expertise from the professionals who care for these patients. Specifically, the Tandem X2:slim with Control-IQ technology system, due to its features and configuration options and adjustments, allows T1D patients to better adapt the management of diabetes to multiple circumstances in their day-to-day life. It is necessary, however, to follow a systematic process to start the system and also for the subsequent follow-up, which allows its optimization in the shortest possible time. This expert recommendation reviews the main features of this HCL system, suggesting how to implement it and optimize its use after gaining experience treating many patients.Keywords
This publication has 15 references indexed in Scilit:
- Closed-Loop Insulin Delivery Systems: Past, Present, and Future DirectionsFrontiers in Endocrinology, 2022
- One Year Real-World Use of the Control-IQ Advanced Hybrid Closed-Loop TechnologyDiabetes Technology & Therapeutics, 2021
- Safety and Performance of the Tandem t:slim X2 with Control-IQ Automated Insulin Delivery System in Toddlers and PreschoolersDiabetes Technology & Therapeutics, 2021
- Closed-Loop Insulin Therapy Improves Glycemic Control in Adolescents and Young Adults: Outcomes from the International Diabetes Closed-Loop TrialDiabetes Technology & Therapeutics, 2021
- Clinical Management and Pump Parameter Adjustment of the Control-IQ Closed-Loop Control System: Results from a 6-Month, Multicenter, Randomized Clinical TrialDiabetes Technology & Therapeutics, 2021
- Extended Use of the Control-IQ Closed-Loop Control System in Children With Type 1 DiabetesDiabetes Care, 2021
- Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Based on Total Daily Insulin in Adolescents with Type 1 DiabetesDiabetes Technology & Therapeutics, 2020
- Six-Month Randomized, Multicenter Trial of Closed-Loop Control in Type 1 DiabetesNew England Journal of Medicine, 2019
- Clinical Targets for Continuous Glucose Monitoring Data Interpretation: Recommendations From the International Consensus on Time in RangeDiabetes Care, 2019
- Successful At-Home Use of the Tandem Control-IQ Artificial Pancreas System in Young Children During a Randomized Controlled TrialDiabetes Technology & Therapeutics, 2019